Atara Biotherapeutics, Inc. (ATRA) News
Filter ATRA News Items
ATRA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ATRA News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ATRA News From Around the Web
Below are the latest news stories about ATARA BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate ATRA as an investment opportunity.
Here's Why You Should Consider Buying Atara Biotherapeutics StockHere, we discuss some reasons why buying ATRA stock now may turn out to be a prudent move. |
Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) high institutional ownership speaks for itself as stock continues to impress, up 27% over last weekKey Insights Given the large stake in the stock by institutions, Atara Biotherapeutics' stock price might be vulnerable... |
Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's WhyAtara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register NowMIAMI, Dec. 04, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 77th Emerging Growth Conference on December 4 & 5, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compa |
Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx ConferenceTHOUSAND OAKS, Calif., November 27, 2024--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Cokey Nguyen, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 3:50 p.m. EST. |
Atara Biotherapeutics Third Quarter 2024 Earnings: Beats ExpectationsAtara Biotherapeutics ( NASDAQ:ATRA ) Third Quarter 2024 Results Key Financial Results Revenue: US$40.2m (up by... |
Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare ConferenceTHOUSAND OAKS, Calif., November 13, 2024--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Cokey Nguyen, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Monday, November 18, 2024 at 6:10 a.m. PST / 9:10 a.m. EST. |
Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue EstimatesAtara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 22.28% and 74.74%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Atara Biotherapeutics: Q3 Earnings SnapshotTHOUSAND OAKS, Calif. AP) — Atara Biotherapeutics Inc. ATRA) on Tuesday reported a loss of $21.9 million in its third quarter. |
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational ProgressTHOUSAND OAKS, Calif., November 12, 2024--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2024, recent business highlights, and key upcoming milestones. |